Valuation : Sensorion

Market Cap 14Cr 16Cr 13Cr 12Cr 22Cr 1.51TCr 22Cr 152.26Cr 59Cr 766.27Cr 60Cr 58Cr 2.54TCr P/E 2026 *
-35.5x
P/E 2027 * -5.91x
Enterprise Value 49.15L 56.98L 46.24L 42.12L 79.21L 54Cr 79.64L 5.47Cr 2.13Cr 28Cr 2.14Cr 2.09Cr 91Cr EV / Sales 2026 *
0.22x
EV / Sales 2027 * 21.4x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
1 day-1.29%
1 week-2.55%
Current month-1.29%
1 month-3.78%
3 months-35.31%
6 months-26.60%
Current year-21.03%
1 week 0.23
Extreme 0.229
0.24
1 month 0.23
Extreme 0.229
0.25
Current year 0.19
Extreme 0.1902
0.65
1 year 0.19
Extreme 0.1902
0.65
3 years 0.12
Extreme 0.121
0.98
5 years 0.12
Extreme 0.121
2.24
10 years 0.12
Extreme 0.121
2.89
Manager TitleAgeSince
Chief Executive Officer 59 01/06/2026
Director of Finance/CFO - 26/06/2024
Chief Tech/Sci/R&D Officer - 11/12/2023
Director TitleAgeSince
Director/Board Member - 09/03/2015
Director/Board Member 43 -
Chairman 61 30/03/2023
Change 5-day change 1-year change 3-year change Capi.($)
-1.29%-2.55% - - 16Cr
+0.21%-1.70%+1.90%+18.18% 4.98TCr
+2.09%-0.81%+452.73%+517.81% 4.41TCr
-1.09%-0.73%+35.40%+16.04% 4.3TCr
-0.26%-3.58%+17.19%+72.80% 4.09TCr
-0.48%-3.09%+17.78%+49.80% 3.31TCr
-1.81%-5.94%+22.65%+115.79% 1.66TCr
-1.06%+3.29% - - 1.73TCr
-1.35%-2.32%+10.40%+25.90% 1.46TCr
-2.05%-5.44%+72.89%+36.51% 1.38TCr
Average -0.81%-1.64%+78.87%+106.61% 3.03TCr
Weighted average by Cap. -0.40%-1.79%+95.32%+124.45%

Financials

2026 *2027 *
Net sales 2.19Cr 2.53Cr 2.06Cr 1.87Cr 3.52Cr 240.49Cr 3.54Cr 24Cr 9.46Cr 122.33Cr 9.51Cr 9.31Cr 405.63Cr 63.95L 74.14L 60.15L 54.8L 1.03Cr 70Cr 1.04Cr 7.11Cr 2.77Cr 36Cr 2.78Cr 2.72Cr 118.68Cr
Net income -2L -3L -2L -2L -4L -2.6Cr -4L -26.32L -10.24L -1.32Cr -10.3L -10.08L -4.39Cr -3.61Cr -4.19Cr -3.4Cr -3.1Cr -5.82Cr -397.4Cr -5.85Cr -40Cr -16Cr -202.15Cr -16Cr -15Cr -670.3Cr
Net Debt -13Cr -15Cr -12Cr -11Cr -21Cr -1.45TCr -21Cr -146.79Cr -57Cr -738.76Cr -57Cr -56Cr -2.45TCr -
Logo Sensorion
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
63
Date Price Change
01/26/01 €0.2290 -1.29%
31/26/31 €0.2320 -0.85%
28/26/28 €0.2340 0.00%
27/26/27 €0.2340 -1.68%
26/26/26 €0.2380 +2.59%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.2660EUR
Average target price
1.138EUR
Spread / Average Target
+327.63%

Quarterly revenue - Rate of surprise